These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12875524)

  • 1. Factors influencing the development of lipodystrophy in human immunodeficiency virus-infected patients.
    Collazos J; Rodriguez-Guardado A; Maradona JA; Mayo J; Asensi V; Ibarra S; Carton JA; Casado L
    Scand J Infect Dis; 2003; 35(5):339-40. PubMed ID: 12875524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
    Sheng WH; Hung CC; Kao JH; Chang SY; Chen MY; Hsieh SM; Chen PJ; Chang SC
    Clin Infect Dis; 2007 Apr; 44(7):988-95. PubMed ID: 17342655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals.
    Burgi A; Brodine S; Wegner S; Milazzo M; Wallace MR; Spooner K; Blazes DL; Agan BK; Armstrong A; Fraser S; Crum NF
    Cancer; 2005 Oct; 104(7):1505-11. PubMed ID: 16104038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management.
    Verucchi G; Calza L; Manfredi R; Chiodo F
    Infection; 2004 Feb; 32(1):33-46. PubMed ID: 15007741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus.
    Massad LS; Silverberg MJ; Springer G; Minkoff H; Hessol N; Palefsky JM; Strickler HD; Levine AM; Sacks HS; Moxley M; Heather Watts D
    Am J Obstet Gynecol; 2004 May; 190(5):1241-8. PubMed ID: 15167825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
    Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART).
    Lapphra K; Vanprapar N; Phongsamart W; Chearskul P; Chokephaibulkit K
    J Med Assoc Thai; 2005 Jul; 88(7):956-66. PubMed ID: 16241026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low effectiveness of highly active antiretroviral therapy and high mortality in the Greenland HIV-infected population.
    Lohse N; Ladefoged K; Pedersen L; Jensen-Fangel S; Sørensen HT; Obel N
    Scand J Infect Dis; 2004; 36(10):738-42. PubMed ID: 15513400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
    Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination.
    Klein MB; Lu Y; DelBalso L; Coté S; Boivin G
    Clin Infect Dis; 2007 Jul; 45(2):234-40. PubMed ID: 17578785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lipodystrophy in HIV infected children].
    Popielska J
    Pol Merkur Lekarski; 2008 May; 24(143):408-13. PubMed ID: 18634383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy.
    Palacios R; Merchante N; Macias J; González M; Castillo J; Ruiz J; Márquez M; Gómez-Mateos J; Pineda JA; Santos J
    Antivir Ther; 2006; 11(4):529-35. PubMed ID: 16856627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management.
    Hirsch HH; Battegay M
    Infection; 2002 Oct; 30(5):293-8. PubMed ID: 12382089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
    Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
    Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy.
    Sheng WH; Kao JH; Chen PJ; Huang LM; Chang SY; Sun HY; Hung CC; Chen MY; Chang SC
    Clin Infect Dis; 2007 Nov; 45(9):1221-9. PubMed ID: 17918088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
    Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
    Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.
    Sheng WH; Hung CC; Wu RJ; Wang JT; Chen PJ; Chang SC; Kao JH
    Clin Infect Dis; 2007 Feb; 44(4):584-90. PubMed ID: 17243064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.